

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  25D1068573	<b>(X3) Date Survey Completed</b>  09/27/2018
<b>Name of Provider or Supplier</b>  Medplus Starkville Llc	<b>Street Address, City, State</b>  1207 Hwy 182 W, Starkville, MS	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D5447</b>	<p>CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(i)(g)</p> <p>Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each quantitative procedure, include two control materials of different concentrations; (g) The laboratory must document all control procedures performed.</p> <p>This STANDARD is not met as evidenced by: Based on review of quality control (QC) records for the Alfa Wassermann ACE Alera chemistry system from 5-1-18 through 6-26-18 and the laboratory's patient test logs, the laboratory failed to include two controls of different concentrations on each day of total bilirubin testing for six days during this time frame, when twenty-two patient test results were reported. Findings include: Review of QC records for the Alfa Wassermann ACE Alera chemistry system from 5-1-18 through 6-26-18 revealed the laboratory failed to include Level 2, of two levels of control, for total bilirubin on the following days of patient testing: 6-13-18--3 patient test results reported. 6-18-18--5 patient test results reported. 6-20-18--7 patient test results reported. 6-21-18--4 patient test results reported. 6-25-18--2 patient test results reported. 6-26-18--1 patient test result reported.</p>